Latest filings (excl ownership)
15-15D
Suspension of duty to report
6 Jul 20
RW
Registration withdrawal request
6 Jul 20
8-K
Departure of Directors or Certain Officers
29 Jun 20
NT 10-Q
Notice of late quarterly filing
29 Jun 20
10-K
2019 FY
Annual report
1 Jun 20
8-K
Other Events
14 May 20
NT 10-K
Notice of late annual filing
14 May 20
8-K
Other Events
30 Mar 20
8-K
Other Events
27 Mar 20
10-Q
2019 Q3
Quarterly report
14 Nov 19
8-K
Regulation FD Disclosure
27 Sep 19
25-NSE
Exchange delisting
23 Sep 19
8-K
Xynomic Pharma Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma
23 Sep 19
8-K
Departure of Directors or Certain Officers
20 Sep 19
8-K
Regulation FD Disclosure
13 Sep 19
8-K
Entry into a Material Definitive Agreement
6 Sep 19
8-K
Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors
30 Aug 19
8-K
Submission of Matters to a Vote of Security Holders
27 Aug 19
8-K
Regulation FD Disclosure
16 Aug 19
10-Q
2019 Q2
Quarterly report
15 Aug 19
NT 10-Q
Notice of late quarterly filing
15 Aug 19
8-K
Xynomic Pharma Receives Important Accreditation from Independent Ethics Committees of Leading Chinese Cancer Hospitals
7 Aug 19
DEF 14A
Definitive proxy
6 Aug 19
8-K
Xynomic Filed Fast-Track Designation Application for Follicular Lymphoma Treatment with the U.S. FDA
1 Aug 19
8-K
Xynomic Received China Approval to Start 2 Pivotal Lymphoma Clinical Trials
30 Jul 19
PRE 14A
Preliminary proxy
26 Jul 19
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
17 Jul 19
D
$15M in equity / options / securities to be acquired
15 Jul 19
S-1
IPO registration
11 Jul 19
8-K
Entry into a Material Definitive Agreement
11 Jul 19
8-K/A
Entry into a Material Definitive Agreement
5 Jul 19
8-K
Regulation FD Disclosure
21 Jun 19
8-K
Xynomic Completes Pre-IND Meeting with US FDA for XP-102, a Novel Pan-RAF Inhibitor against Colorectal Cancer and Lung Cancer
12 Jun 19
8-K
Other Events
6 Jun 19
8-K
Other Events
21 May 19
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
20 May 19
8-K
Report of Independent Registered Public Accounting Firm
15 May 19
25-NSE
Exchange delisting
15 May 19
25-NSE
Exchange delisting
15 May 19
10-Q
2019 Q1
Quarterly report
14 May 19
Latest ownership filings
SC 13G/A
Xynomic Pharmaceuticals Holdings, Inc.
13 Feb 20
SC 13G/A
Beneficial ownership report (amended)
12 Feb 20
SC 13D/A
Xynomic Pharmaceuticals Holdings, Inc.
6 Jun 19
SC 13D
Xynomic Pharmaceuticals Holdings, Inc.
30 May 19
3
Tingzhi Qian
30 May 19
3
Wentao Jason Wu
30 May 19
SC 13D
Xynomic Pharmaceuticals Holdings, Inc.
30 May 19
SC 13D
Xynomic Pharmaceuticals Holdings, Inc.
29 May 19
3
Yinglin Mark Xu
29 May 19
3
Jinwei Coco Kou
28 May 19
4
Peixin Xu
21 May 19
4
Change in insider ownership
21 May 19
SC 13G/A
Bison Capital Acquisition Corp.
14 Feb 19
SC 13G/A
Beneficial ownership report (amended)
13 Feb 19
SC 13G/A
Bison Capital Acquisition Corp.
12 Feb 19
SC 13G/A
Bison Capital Acquisition Corp.
8 Feb 19
SC 13D
Bison Capital Acquisition Corp.
20 Sep 18
SC 13G
Bison Capital Acquisition Corp.
24 Aug 18
3
Peidong Wu
1 Jun 18
SC 13G
Beneficial ownership report
14 Feb 18
SC 13G
Bison Capital Acquisition Corp.
9 Feb 18
SC 13G
Bison Capital Acquisition Corp.
1 Feb 18
SC 13G
Bison Capital Acquisition Corp.
8 Jan 18
3
Fan Bu
29 Sep 17
4
Change in insider ownership
28 Jun 17
4
Peixin Xu
28 Jun 17
4
Fengyun Jiang
28 Jun 17
SC 13D
Bison Capital Acquisition Corp.
28 Jun 17
SC 13D
Bison Capital Acquisition Corp.
28 Jun 17
3
Initial statement of insider ownership
21 Jun 17
3
Charles Vincent Prizzi
20 Jun 17
3
Ning Wang
20 Jun 17
3
Peng Jin
20 Jun 17
3
Fengyun Jiang
20 Jun 17
3
Peixin Xu
20 Jun 17
3
Thomas Folinsbee
20 Jun 17
3
JAMES JIAYUAN TONG
20 Jun 17